Shore Capital Reiterates Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by stock analysts at Shore Capital in a research note issued on Tuesday, Marketbeat.com reports. They currently have a £135 ($179.00) target price on the biopharmaceutical company’s stock. Shore Capital’s target price points to a potential upside of 17.41% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £110 ($145.85) target price on shares of AstraZeneca in a report on Tuesday, July 8th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 140 ($1.86) price objective on shares of AstraZeneca in a research note on Friday, May 16th.

AstraZeneca Stock Performance

AstraZeneca stock opened at £114.98 ($152.45) on Tuesday. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. The company has a market capitalization of £221.23 billion, a PE ratio of 31.52, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a 50 day moving average price of £105.44 and a 200-day moving average price of £108.74. AstraZeneca has a fifty-two week low of GBX 9,573.51 ($126.94) and a fifty-two week high of £133.88 ($177.51).

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.